Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
The move follows promising but early data presented at ASCO.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Any hopes of differentiation could come down to side effects.
Crunch time approaches for UroGen.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.